GlassScriptPhysician profile
Nameer Aladamat
NPI 1073286597
$1,297.54
in general payments reported to CMS, 2019-2025
25 companies · $465 in 2025
The $465 reported for 2025 was more than what 77% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $73.92 · 2023: $352 · 2024: $407 · 2025: $465.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,223.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $320.39 | 2023-2025 | Briviact, Fintepla |
| Abbvie INC. | $246.16 | 2024-2025 | |
| Neurelis, INC. | $132.32 | 2022-2025 | Valtoco |
| Genentech USA, INC. | $73.47 | 2024-2025 | Ocrevus, Ocrevus Zunovo |
| Acadia Pharmaceuticals INC | $62.64 | 2024-2025 | Nuplazid |
| Takeda Pharmaceuticals U.S.A., INC. | $44.61 | 2023 | |
| Argenx US, INC. | $41.45 | 2023 | Vyvgart |
| Lundbeck LLC | $38.80 | 2024-2025 | Vyepti |
| Sk Life Science, INC. | $34.01 | 2024 | |
| Alexion Pharmaceuticals, INC. | $33.37 | 2024 | Ultomiris |
| Biohaven Pharmaceutical Holding Company LTD. | $32.55 | 2022 | |
| Merz Pharmaceuticals, LLC | $23.10 | 2023 | Xeomin |
| Tg Therapeutics, INC. | $22.92 | 2025 | |
| Csl Behring | $20.96 | 2024 | Hizentra |
| Jazz Pharmaceuticals INC. | $19.83 | 2023 | Epidiolex |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $18.43 | 2024 | Austedo Xr |
| Averitas Pharma INC. | $16.40 | 2023 | Qutenza |
| Genzyme Corporation | $16.31 | 2022 | |
| Biogen, INC. | $15.74 | 2023 | Spinraza |
| Lilly USA, LLC | $15.30 | 2024 | Reyvow, Emgality |
| Emd Serono, INC. | $14.41 | 2024 | |
| Alnylam Pharmaceuticals INC. | $14.37 | 2023 | Onpattro |
| Catalyst Pharmaceuticals, INC. | $14.14 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $13.86 | 2025 | Wainua |
| Horizon Therapeutics Plc | $12.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nameer Aladamat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.